Case: Envision Healthcare Corporation
Court: Middle District of Tennessee
Class Period: 3/2/2015 - 7/21/2017
Lead Plaintiff Deadline: 10/3/2017
Contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NEW YORK, NY – August 22, 2017 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Envision Healthcare Corporation (“Envision Healthcare” or the “Company”) (NYSE: EVHC).  

Class action litigation has been filed in the United States District Court for the Middle District of Tennessee against Envision Healthcare and certain Company executives on behalf of investors who purchased or otherwise acquired Envision Healthcare securities between March 2, 2015 and July 21, 2017, inclusive (the “Class”), alleging violations of the Securities Exchange Act of 1934.

On July 24, 2017, The New York Times reported that hospitals associated with Envision Healthcare’s subsidiary EmCare were disproportionately likely to engage in “surprise billing,” in which patients who sought treatment at in-network facilities were treated by out-of-network physicians and subsequently billed at higher rates.

Following this news, Envision Healthcare’s share price fell $2.33 per share, or 3.72%, to close at $60.28 per share on July 24, 2017.

The complaint alleges that throughout the Class Period, the defendants made materially false and/or misleading statements and/or failed to disclose that (1) EmCare routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians, (2) EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians, (3) the Company’s statements attributing EmCare’s Class Period growth to other factors were therefore false and/or misleading, and (4) Envision Healthcare’s EmCare revenues were likely to be unsustainable after the foregoing conduct came to light.  

If you are a member of the proposed Class, you may move the court no later than October 3, 2017 to serve as a lead plaintiff for the purported class.  You need not seek to become a lead plaintiff in order to share in any possible recovery.  If you would like to discuss the complaint or our investigation, please contact us by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it or by calling 800-290-1952.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  
If you have any questions about this Notice, the action, your rights, or your interests, please contact: 

Frederic S. Fox
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952(212) 687-1980
Fax: (212) 687-7714
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
350 Sansome Street, Suite 400 
San Francisco, California  
94104(415) 772-4700
Fax:  (415) 772-4707
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it


Attorneys: Laurence D. King, Frederic S. Fox Pamela A. Mayer